ID   CML-6M
AC   CVCL_0D24
SY   CML_6M; CML6M
DR   GEO; GSM1974782
DR   Wikidata; Q54813799
RX   PubMed=3434911;
RX   PubMed=8239507;
RX   PubMed=15965647;
RX   PubMed=21908323;
RX   PubMed=22901430;
RX   PubMed=23410087;
RX   PubMed=27197945;
RX   PubMed=27257868;
RX   PubMed=31175136;
CC   Part of: FACC canine tumor cell line panel.
CC   Characteristics: Pigmented.
CC   Doubling time: 15 hours (PubMed=27257868).
CC   Sequence variation: Mutation; VGNC; VGNC:43761; NF1; Simple; p.Pro1599fs (c.4795delCinsTT); Zygosity=Heterozygous (PubMed=31175136).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029.
CC   Breed/subspecies: Mixed breed; VBO=VBO_0200902.
ST   Source(s): PubMed=27197945; PubMed=31175136
ST   Dog FHC2010: 235,239
ST   Dog FHC2054: 151
ST   Dog FHC2079: 275
ST   Dog PEZ1: 119,127
ST   Dog PEZ3: 127,134
ST   Dog PEZ5: 103
ST   Dog PEZ6: 179
ST   Dog PEZ8: 236,240
ST   Dog PEZ12: 277,297
ST   Dog PEZ20: 172,180
DI   NCIt; C120298; Canine melanoma
OX   NCBI_TaxID=9615; ! Canis lupus familiaris (Dog)
SX   Sex unspecified
AG   8Y
CA   Cancer cell line
DT   Created: 10-04-15; Last updated: 19-12-24; Version: 14
//
RX   PubMed=3434911;
RA   Wolfe L.G., Oliver J.L. 3rd, Smith B.B., Toivio-Kinnucan M.A.,
RA   Powers R.D., Brawner W.R., Henderson R.A., Hankes G.H.;
RT   "Biologic characterization of canine melanoma cell lines.";
RL   Am. J. Vet. Res. 48:1642-1648(1987).
//
RX   PubMed=8239507;
RA   Ahern T.E., Bird R.C., Church Bird A.E., Wolfe L.G.;
RT   "Overexpression of c-erbB-2 and c-myc but not c-ras, in canine
RT   melanoma cell lines, is associated with metastatic potential in nude
RT   mice.";
RL   Anticancer Res. 13:1365-1371(1993).
//
RX   PubMed=15965647; DOI=10.1007/s00262-005-0025-6; PMCID=PMC11031070;
RA   Alexander A.N., Huelsmeyer M.K., Mitzey A., Dubielzig R.R.,
RA   Kurzman I.D., MacEwen E.G., Vail D.M.;
RT   "Development of an allogeneic whole-cell tumor vaccine expressing
RT   xenogeneic gp100 and its implementation in a phase II clinical trial
RT   in canine patients with malignant melanoma.";
RL   Cancer Immunol. Immunother. 55:433-442(2006).
//
RX   PubMed=21908323; DOI=10.1177/1040638711408064;
RA   O'Donoghue L.E., Rivest J.P., Duval D.L.;
RT   "Polymerase chain reaction-based species verification and
RT   microsatellite analysis for canine cell line validation.";
RL   J. Vet. Diagn. Invest. 23:780-785(2011).
//
RX   PubMed=22901430; DOI=10.1016/j.jcpa.2012.07.001; PMCID=PMC3535688;
RA   Chon E., Thompson V., Schmid S., Stein T.J.;
RT   "Activation of the canonical Wnt/beta-catenin signalling pathway is
RT   rare in canine malignant melanoma tissue and cell lines.";
RL   J. Comp. Pathol. 148:178-187(2013).
//
RX   PubMed=23410087; DOI=10.1111/vco.12019;
RA   Wilson-Robles H.M., Daly M., Pfent C., Sheppard-Olivares S.;
RT   "Identification and evaluation of putative tumour-initiating cells in
RT   canine malignant melanoma cell lines.";
RL   Vet. Comp. Oncol. 13:60-69(2015).
//
RX   PubMed=27197945; DOI=10.1111/vco.12192; PMCID=PMC5656225;
RA   Fowles J.S., Dailey D.D., Gustafson D.L., Thamm D.H., Duval D.L.;
RT   "The Flint Animal Cancer Center (FACC) canine tumour cell line panel:
RT   a resource for veterinary drug discovery, comparative oncology and
RT   translational medicine.";
RL   Vet. Comp. Oncol. 15:481-492(2017).
//
RX   PubMed=27257868; DOI=10.1371/journal.pone.0156689; PMCID=PMC4892608;
RA   Maeda J., Froning C.E., Brents C.A., Rose B.J., Thamm D.H., Kato T.A.;
RT   "Intrinsic radiosensitivity and cellular characterization of 27 canine
RT   cancer cell lines.";
RL   PLoS ONE 11:E0156689-E0156689(2016).
//
RX   PubMed=31175136; DOI=10.1158/1535-7163.MCT-18-1346; PMCID=PMC6679748;
RA   Das S., Idate R., Cronise K.E., Gustafson D.L., Duval D.L.;
RT   "Identifying candidate druggable targets in canine cancer cell lines
RT   using whole-exome sequencing.";
RL   Mol. Cancer Ther. 18:1460-1471(2019).
//